590 filings
Page 3 of 30
DEFA14A
qtuqv z33nq
29 Sep 22
Additional proxy soliciting materials
4:16pm
8-K
bcc69
29 Sep 22
Other Events
4:15pm
8-K
94dj6adp
26 Sep 22
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA
4:08pm
8-K
ybz47so
15 Aug 22
9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022
7:03am
8-K
2l06wtssy6f gd1y
10 Aug 22
Other Events
12:00am
EFFECT
3u5no5345qsv 7t
5 Aug 22
Notice of effectiveness
12:15am
424B3
aotz6y24bgoi 9dpv
4 Aug 22
Prospectus supplement
4:17pm
CORRESP
2x9f 4pw8foclrf6r
2 Aug 22
Correspondence with SEC
12:00am
UPLOAD
cvyso2
1 Aug 22
Letter from SEC
12:00am
4/A
s33umt92
22 Jul 22
9 METERS BIOPHARMA / Mark A Sirgo ownership change
4:21pm
SC 13G
sjkeaj47wors9k6
8 Jul 22
9 METERS BIOPHARMA / BlackRock ownership change
4:57pm
4
j6mjbfbc
8 Jul 22
9 METERS BIOPHARMA / John Temperato ownership change
8:01am
4
o25v9wbtiojlsz
6 Jul 22
9 METERS BIOPHARMA / Mark A Sirgo ownership change
4:43pm
SC 13D/A
yghisg0m1kyxo3zzmm
1 Jul 22
9 METERS BIOPHARMA / OrbiMed Israel BioFund GP Limited Partnership ownership change
5:20pm
8-K
est24
30 Jun 22
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
8:18am
8-K
nzpvr49kxu
30 Jun 22
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
7:06am